Oncovin and Premature baby - a phase IV clinical study of FDA data

Summary:

Premature baby is reported as a side effect among people who take Oncovin (vincristine sulfate), especially for people who are female, 0-1 old, have been taking the drug for < 1 month also take Cyclophosphamide, and have Foetal exposure during pregnancy.

The phase IV clinical study analyzes which people have Premature baby when taking Oncovin. It is created by eHealthMe based on reports of 6,660 people who have side effects when taking Oncovin from the FDA, and is updated regularly.

What is Oncovin?

Oncovin has active ingredients of vincristine sulfate. eHealthMe is studying from 6,667 Oncovin users. Check the latest studies of Oncovin.

What is Premature baby?

Premature baby is found to be associated with 915 drugs and 1,093 conditions by eHealthMe. Check the latest studies of Premature baby.

On Jul, 19, 2026

6,660 people reported to have side effects when taking Oncovin.
Among them, 29 people (0.44%) have Premature baby.

Among these 29 people:

How long have people been on Oncovin when they have Premature baby? *

What is the gender of people who have Premature baby when taking Oncovin? *

female: 73.91 %
male: 26.09 %

What is the age of people who have Premature baby when taking Oncovin? *

What are other drugs people take besides Oncovin? *

What are other side effects people have besides Premature baby? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 13 people, 44.83%
Low Birth Weight Baby: 7 people, 24.14%
Jaundice Neonatal (yellowing of skin in neonate): 7 people, 24.14%
Gamma-Glutamyltransferase Increased: 6 people, 20.69%
Birth Control: 5 people, 17.24%
Neonatal Cholestasis (accumulation of components of bile in the bloodstream in neonate): 4 people, 13.79%
Anaemia (lack of blood): 4 people, 13.79%
Drug Exposure During Pregnancy: 4 people, 13.79%
Foetal Growth Restriction (poor growth of a baby while in the mother's womb during pregnancy): 3 people, 10.34%
Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 3 people, 10.34%

What are the existing conditions these people have? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 8 people, 27.59%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 6.90%
Malignant Histiocytosis (cancerous increase in the number of immune cells): 1 person, 3.45%
Lymphoma (cancer that begins in immune system cells): 1 person, 3.45%
B Precursor Type Acute Leukaemia (lymphoid cancer): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Oncovin and have Premature baby?

- Check whether Premature baby is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oncovin:

Oncovin (6,667 reports)

Premature baby treatments and more:

Premature baby (40,768 reports)

Browse all side effects of Oncovin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Premature baby:

Premature baby (915 drugs)

Browse all the conditions that are associated with Premature baby:

Premature baby (1,093 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vincristine sulfate (the active ingredients of Oncovin) and Oncovin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.